GLP-1 (7–36) amide vs Glucagon

How they're alike

GLP-1 (7–36) amide and glucagon are family members in the strictest biochemical sense — both are bioactive peptides cleaved from the same proglucagon precursor by tissue-specific prohormone processing, with pancreatic alpha cells releasing glucagon and intestinal L-cells releasing GLP-1, GLP-2, oxyntomodulin and glicentin (Lafferty 2021, Gasbjerg 2026). That common ancestry is visible in the sequences themselves: BLOSUM62 local alignment of the two 29/30-residue peptides gives 51.9% identity over a 27-residue stretch (14 of 27 positions identical), with the central GTF...SDY...DF motif conserved between them. Both peptides also signal through closely related class B (secretin-family) G-protein-coupled receptors — GCGR for glucagon and GLP-1R for GLP-1 — that share the canonical two-domain binding mode in which a large extracellular N-terminal domain captures the peptide's C-terminal half while the transmembrane bundle engages the N-terminal residues (Donnelly 2012, Graaf 2016). Functionally, both peptides participate in coordinated post-prandial and inter-prandial glucose homeostasis, and both are reviewed together as components of proglucagon-derived peptide pharmacology (Gasbjerg 2026, Lafferty 2021).

How they differ

The decisive mechanistic difference is direction. Glucagon at GCGR mobilises stored glucose: in hepatocytes it engages adenylyl cyclase, raises cAMP and activates PKA, which phosphorylates glycogen phosphorylase and inhibits glycogen synthase, releasing hepatic glycogen into circulation, while also activating gluconeogenic enzymes for de novo glucose production (readme_a). GLP-1 (7–36) amide at GLP-1R does the opposite at the systems level — it potentiates glucose-dependent insulin secretion from pancreatic β-cells (Meloni 2013, Seino 2010), suppresses α-cell glucagon secretion, slows gastric emptying, and promotes satiety via central appetite circuits (Donnelly 2012, Farhadipour 2021). Both engage Gαs–cAMP signalling at the receptor level, but in different tissues with opposing physiological outputs: glucagon raises glucose, GLP-1 lowers post-prandial glucose excursions.

Pharmacokinetics is the other axis of difference and the reason their therapeutic trajectories diverged. Native GLP-1 (7–36) amide is cleaved between Ala8 and Glu9 by dipeptidyl peptidase-4 (DPP-4), abolishing receptor binding within minutes — which is why the GLP-1 therapeutic field consists of engineered DPP-4-resistant, albumin-binding analogs (semaglutide, liraglutide, exenatide, tirzepatide) rather than the native peptide itself (Graaf 2016, Galindo 2026). Glucagon's plasma half-life is longer (approximately 8–18 minutes per the FDA label summary), which together with the acute single-dose use case made it tractable as a directly administered drug as early as 1960 (Isaacs 2021, readme_a). Their sequence-level relationship is also asymmetric in that GLP-1 carries a C-terminal amide — implied by the "(7–36) amide" naming and not visible in any one-letter sequence string — whereas the marketed glucagon products are unmodified linear 29-mers (Donnelly 2012, readme_a).

Head-to-head clinical evidence

No randomised trial in the dossier directly compares native GLP-1 (7–36) amide and native glucagon as alternative interventions in the same patient population — this is expected because the two peptides have non-overlapping clinical use cases (hypoglycemia rescue for glucagon; research-probe infusions and reference-ligand status for native GLP-1). The closest study designs in the head-to-head candidate set are mechanistic GLP-1 infusion trials in patients with type 2 diabetes that report glucagon as a measured endpoint rather than as a comparator arm — for example continuous GLP-1 administration near-normalising diurnal glucose in NIDDM (Diabetologia 1997 and subcutaneous GLP-1 (7–36 amide) abolishing postprandial glycaemia in NIDDM (Diabetes Care 1994 The functional opposition is also visible in mechanistic work: Salehi and colleagues blocked endogenous GLP-1R signalling with exendin-(9–39) in people with and without type 2 diabetes and showed that endogenous GLP-1 contributes meaningfully to post-prandial insulin secretion in both groups, with concomitant changes in α-cell glucagon output (Salehi 2010). For a directly comparable head-to-head between the two peptides as drugs, the relevant therapeutic frame in the dossier is the dual/triple receptor agonist class (mazdutide, survodutide, retatrutide), where glucagon and GLP-1 receptor agonism are deliberately combined in a single molecule rather than compared as separate ones (Lafferty 2021, readme_a).

Safety profile comparison

The two peptides have very different safety footprints because they are used differently. The glucagon FDA-label profile centres on acute single-dose rescue use: commonly reported nausea, vomiting (patients should be turned on their side after rescue because vomiting is common as blood sugar rises), headache, transient hyperglycemia and rebound hypoglycemia within 1–2 hours if oral carbohydrate is not consumed; rare anaphylactic and hypersensitivity reactions; and ineffectiveness in glycogen-depleted states (prolonged starvation, severe hepatic disease, chronic alcohol use, adrenal insufficiency), where the labeled appropriate intervention is IV dextrose (Isaacs 2021, readme_a). The systematic-review evidence on glucagon for hypoglycemia rescue (Boido 2014) places it as a well-characterised acute intervention. Glucagon also carries label contraindications for pheochromocytoma (catecholamine release), insulinoma (paradoxical insulin surge) and glucagonoma (readme_a).

Native GLP-1 (7–36) amide has no FDA label of its own because it is not a marketed drug; its short-infusion safety profile in mechanistic studies has not surfaced as a barrier to research use (Kreymann 1987, Salehi 2010), but the clinically relevant adverse-event experience associated with GLP-1R activation comes from the engineered analogs rather than the native peptide. Notably, because GLP-1R signalling is glucose-dependent, GLP-1-based drugs carry a lower hypoglycaemia risk than sulphonylureas — a property the native peptide also shares mechanistically (Meloni 2013). Glucagon receptor agonism, by contrast, is intentionally hyperglycaemic; this is the labeled pharmacology in the rescue setting (Isaacs 2021).

Indication overview

Glucagon is FDA-approved as a prescription drug across multiple formulations: GlucaGen (Novo Nordisk reconstituted injection), Lilly Glucagon Emergency Kit (reconstituted injection), Baqsimi (Lilly intranasal powder, 2019) and Gvoke HypoPen / Gvoke PFS (Xeris pre-mixed liquid auto-injector and pre-filled syringe, 2019), with parallel approvals from EMA, MHRA, Health Canada and TGA per the card source (readme_a, Isaacs 2021). Approved indications are emergency reversal of severe hypoglycemia in insulin-treated diabetic patients with intact hepatic glycogen, and as a diagnostic aid for smooth-muscle relaxation during gastrointestinal imaging (readme_a).

GLP-1 (7–36) amide as the native peptide is not a marketed drug in any major jurisdiction; it is used clinically as a research probe (short infusions) and as the biological reference ligand against which engineered GLP-1R agonists are characterised (Graaf 2016, Galindo 2026, readme_b). The marketed agents in this therapeutic class — semaglutide, liraglutide, exenatide, tirzepatide — are engineered analogs of GLP-1 rather than the native peptide, and they each have their own approved indications and regulatory packages that are not properties of GLP-1 (7–36) amide itself (Graaf 2016). The two peptides thus occupy different therapeutic roles: glucagon as a deployable rescue drug, native GLP-1 as the parent ligand whose biology motivated an entire class of derivative medicines.